evaluation of adverse drug events of remdesivir for the treatment of covid-19 in patients contacting the 13-aban pharmacy drug and poison information center

Background: one of the fda-approved treatments for covid-19 is remdesivir. in this study, we investigated adverse drug events (ades) of remdesivir in covid-19 patients who contacted 13-aban pharmacy’s drug and poison information center (dpic). methods: in this study, data of patients receiving remdesivir who contacted the 13-aban pharmacy’s dpic between april 2021 and may 2022 were extracted. for the evaluation of potential ades, we reviewed all contacts related to remdesivir recipients. results: out of 223 patients enrolled, 108 (48.40%) developed 120 ades. elevated liver transaminase levels (26.67%) were the most common ade, followed by weakness (7.5%), nausea, and vomiting (7.5%). the causality assessment of ade using the naranjo scale revealed that 41.67% were probable and 58.33% were possible. conclusion: based on the results of this study, hepatic dysfunction was the most prevalent ade among remdesivir recipients; thus, in order to ensure safe use of remdesivir, patients should be closely monitored for this ade.